» Articles » PMID: 35602582

Highly Diluted Antibodies to ENOS Restore Endothelium Function in Aortic Rings From Hypertensive Rats

Overview
Journal Dose Response
Publisher Sage Publications
Date 2022 May 23
PMID 35602582
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nitric oxide (NO) as a vaso- and cardio-protective agent could reduce vasomotor dysfunction in different cardiovascular diseases. One of the current therapeutics targeted at NO availability in the vascular wall are highly diluted antibodies to endothelial NO-synthase (eNOS). This drug has previously shown its endothelium-protective effect and effectiveness in reducing hypertension. Current study was dedicated to evaluate the direct impact of highly diluted antibodies to eNOS on the vessel constriction and dilation ex vivo.

Methods: For that purpose, we used thoracic aortas dissected from spontaneously hypertensive (SHR) rats. Endothelium-dependent relaxation in the presence of highly diluted antibodies to eNOS (1 mL) was examined after phenylephrine-induced pre-constriction of the aorta rings in response to gradually increased acetylcholine concentration (1 nM to 10 µM).

Results: Highly diluted antibodies to eNOS enhanced acetylcholine-induced relaxation in a statistically significant manner. Moreover, it was demonstrated that observed effect was similar to perindopril, a well-known angiotensin-converting-enzyme inhibitor, which works through relaxing and widening blood vessels.

Conclusions: Our findings indicate that highly diluted antibodies to eNOS restored impaired endothelium function, as demonstrated by increased relaxation of SHR rats aorta rings. The revealed results suggest beneficial effect of highly diluted antibodies to eNOS to ameliorate hypertension and related diseases.

References
1.
Sandoo A, Veldhuijzen van Zanten J, Metsios G, Carroll D, Kitas G . The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J. 2011; 4:302-12. PMC: 3040999. DOI: 10.2174/1874192401004010302. View

2.
Yang Q, Xue H, Wong W, Tian X, Huang Y, Tsui S . AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats. Br J Pharmacol. 2011; 163(5):1078-85. PMC: 3130953. DOI: 10.1111/j.1476-5381.2011.01308.x. View

3.
Hickey H, Makdissi M, Hyland R, Wilks D, Dusting G . Perindopril treatment prevents the loss of endothelial nitric oxide function and development of neo-intima in rabbits. J Mol Cell Cardiol. 1996; 28(9):1985-94. DOI: 10.1006/jmcc.1996.0191. View

4.
Hou H, Wang J, Zhang X, Wang Z, Chen T, Zhang J . Endothelial nitric oxide synthase enhancer AVE3085 reverses endothelial dysfunction induced by homocysteine in human internal mammary arteries. Nitric Oxide. 2018; 81:21-27. DOI: 10.1016/j.niox.2018.10.001. View

5.
Chikramane P, Kalita D, Suresh A, Kane S, Bellare J . Why extreme dilutions reach non-zero asymptotes: a nanoparticulate hypothesis based on froth flotation. Langmuir. 2012; 28(45):15864-75. DOI: 10.1021/la303477s. View